Although GI AEs are common across all GLP-1 RAs, differences in formulation, dosing, and dual agonism with tirzepatide can influence how well patients tolerate therapy
According to the Ozempic label, the FDA has only approved it for managing blood glucose and reducing the risk of sustained eGFR decline, end-stage kidney disease, and major cardiovascular events in people with Type 2 diabetes
It is also either ineffective or marginally effective even for the made-up condition for which it was approved, Fugh-Berman writes
Shimamoto, G., Gegg, C., Boone, T
Gluckman and his colleagues provide a clearer picture for clinicians and patients alike, guiding better-informed decisions in the fight against obesity
Overall, we found that methylphenidate, amphetamines, and atomoxetine were significantly more efficacious than placebo in improving QoL in people with ADHD